Borish Loushambam

Mr. Borish Loushambam

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in Neuroglia
Verified
Journal Article
Open access
PDF file
BLBorish Loushambam
Borish Loushambam
MSMirinrinchuiphy M. K. Shimray
Mirinrinchuiphy M. K. Shimray
RKReema Khangembam
Reema Khangembam
VKVenkateswaran Krishnaswami
Venkateswaran Krishnaswami
Sivakumar VijayaraghavaluSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Brain cancer is a heterogeneous collection of malignant neoplasms, such as glioblastoma multiforme (GBM), astrocytomas and medulloblastomas, with high morbidity and mortality. Its treatment is complicated by the tumor’s site, infiltrative growth mode and selective permeability of the blood–brain barrier (BBB). During tumor formation, the BBB dynamically remodels into the blood–brain tumor barrier (BBTB), disrupting homeostasis and preventing drug delivery. Furthermore, the TME (Tumor Micro Environment) supports drug resistance, immune evasion and treatment failure. This review points out the ways in which nanomedicine overcomes these obstacles with custom-designed delivery systems, sophisticated diagnostics and personalized therapies. Traditional treatments fail through a lack of BBB penetration, non-specific cytotoxicity and swift tumor adaptation. Nanomedicine provides greater drug solubility, protection against enzymatic degradation, target drug delivery and control over the release. Nanotheranostics’ confluence of therapeutic and diagnostic modalities allows for dynamic adjustment and real-time monitoring. Nanotechnology has paved the way for the initiation of a new era in precision neuro-oncology. Transcending the limitations of conventional therapy protocols, nanomedicine promises to deliver better outcomes by way of enhanced targeting, BBB penetration and real-time monitoring. Multidisciplinary collaboration, regulatory advancements and patient-centered therapy protocols customized to the individual patient’s tumor biology will be necessary to facilitate translation success in the future.

21 February 2025 in Neuroglia
Verified
Journal Article
Open access
PDF file
BLBorish Loushambam
Borish Loushambam
SYSangeeta Yanglem
Sangeeta Yanglem
VKVenkateswaran Krishnaswami
Venkateswaran Krishnaswami
MKMUNISH of KUMAR
MUNISH of KUMAR
Sivakumar VijayaraghavaluSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Background: Neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, and spinal cord injury (SCI) are significant global health challenges due to their complex pathology and limited therapeutic options. Conventional treatments often fail to efficiently cross the blood–brain barrier (BBB), leading to poor bioavailability and systemic toxicity. This narrative review explores the potential of nanomedicine in addressing these limitations and advancing targeted therapies for neural disorders. Methods: This review examines recent studies on the use of engineered nanoparticles (NPs), including liposomes, dendrimers, micelles, and nanogels, for targeted drug delivery and multifunctional theranostics in neural diseases. It evaluates their role in promoting axon regeneration, reducing neuroinflammation, and repairing neural damage. Additionally, innovative applications in gene therapy and RNA-based treatments, such as CRISPR-Cas9 and RNA interference (RNAi), are discussed. Challenges related to toxicity, scalability, affordability, and regulatory barriers are highlighted, along with potential strategies to address these issues. Results: Nanoparticles have shown significant promise in crossing the BBB, delivering therapeutic agents to neural tissues, and minimizing off-target effects. Emerging applications in gene and RNA-based therapies demonstrate their versatility in addressing disease-specific challenges. However, unresolved issues such as long-term safety, manufacturing scalability, and cost continue to pose challenges. Conclusions: Nanomedicine offers a promising approach to overcoming current limitations in the treatment of neural disorders. This review emphasizes the need for continued interdisciplinary efforts to address translational barriers and highlights the potential for nanomedicine to improve the outcomes and quality of life for patients with neural disorders, stroke, and SCI.

Verified
Journal Article
Open access
PDF file
BLBorish Loushambam
Borish Loushambam
VKVenkateswaran Krishnaswami
Venkateswaran Krishnaswami
MKMUNISH of KUMAR
MUNISH of KUMAR
SVSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Insulin injection remains the best therapy for diabetes mellitus, but subcutaneous injection continues to pose challenges, including patient discomfort, poor compliance and fluctuating plasma glucose profiles. Recently, transdermal insulin delivery has emerged as a non-invasive strategy that bypasses gastrointestinal degradation and first-pass hepatic metabolism, thereby increasing insulin bioavailability and enhancing patient acceptance. Recent developments in nanomedicine have facilitated the development of transdermal patches with enhanced drug encapsulation, uptake and controlled release. Nanostructured lipid carriers, polymeric nanocomposites, liposomes and SLNs have demonstrated a five-fold enhancement of transdermal flux and an extended insulin effect in preclinical models. The addition of ionic liquids and polymeric nanogels leads to an additional increase in insulin aqueous solubility and permeation, resulting from the temporary regulation of stratum corneum lipid organization. Bright and stimuli-responsive patches with glucose oxidase or phenylboronic acid functional groups enable regulated insulin delivery in response to changes in blood glucose, demonstrating near-normoglycemia for up to 48 h in animal testing. Nanocomposite systems assisted by microneedles have also been advanced to the early clinical phase, offering enhanced reproducibility of their pharmacokinetics and a low risk of dermal irritation. Despite these encouraging results, several translational challenges remain, such as biocompatibility, repeatability in the production of nanocarriers, long-term stability of formulations and regulatory standardization. This review examines the physicochemical design principles, materials innovations and permeation mechanism of nanomedicine-engineered insulin patches, the current state of preclinical and clinical advancements, challenges in production and future perspectives in viable patient-focused transdermal insulin delivery.

13 August 2026 in Neuroglia
Verified
Journal Article
Open access
PDF file
SYSangeeta Yanglem
Sangeeta Yanglem
BLBorish Loushambam
Borish Loushambam
SSSorokhaibam Mexico Singh
Sorokhaibam Mexico Singh
SVSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Neurotoxicity is generally thought to result from exogenous agents like environmental chemicals, drugs and biological toxins. However, increasing evidence suggests that many endogenous molecules that play a critical role in normal brain function can become neurotoxic when the regulatory mechanism involved in their production, metabolism, compartmentalization and clearance are disrupted. This shift underlies the basis of endogenous neurotoxicity. This review discusses the major endogenous sources of neurotoxicity: metabolic neurotoxins, dysfunctional neurotransmitters, protein aggregates and inflammatory mediators. These endogenous factors arise from different physiological pathways, but share common pathogenic mechanisms, all of which involve an underlying state of oxidative stress, mitochondrial dysfunction, impaired proteostasis, excitotoxic signalling, neurovascular dysfunction and maladaptive neuroglial responses. This is not a singular process but a network of interconnected processes, which work together to progressively diminish neuronal resilience and promote synaptic dysfunction and neurodegeneration. The review also underscores the critical role of astrocytes, microglia and other glial cells in the maintenance of neuronal homeostasis. By integrating diverse endogenous neurotoxic pathways within a unified homeostasis-centred framework, this review provides a broader perspective on the mechanisms linking metabolic disorders, aging and neurodegenerative diseases. This framework suggests that effective therapeutic strategies may require restoration of physiological regulatory networks rather than targeting individual neurotoxic molecules in isolation. A systems-level understanding of endogenous neurotoxicity may therefore facilitate the development of earlier biomarkers and more effective interventions aimed at preserving neuronal homeostasis and preventing progressive neurological dysfunction.

Verified
Journal Article
Open access
PDF file
BLBorish Loushambam
Borish Loushambam
MSMirinrinchuiphy M. K. Shimray
Mirinrinchuiphy M. K. Shimray
VKVenkateswaran Krishnaswami
Venkateswaran Krishnaswami
SVSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Protein therapeutics such as insulin, monoclonal antibodies, peptide hormones, cytokines, enzymes and vaccine antigens have revolutionized the treatment of chronic and complex diseases, but are currently constrained by adherence issues with frequent injection, cold-chain requirements and their intrinsic vulnerability to structural degradation. Dissolving microneedle (DMN) patches have recently been identified as a transdermal platform which allows minimally invasive, self-administered drug delivery and solid-state stabilization of fragile biologics. However, it is a significant challenge to keep the structural integrity and biological activity of proteins when developing the formulation, fabricating the microneedles, drying, storing the fabricates, and applying them to the skin. The mechanisms of molecular degradation (e.g., unfolding, aggregation, fibrillation, oxidation, deamidation, interface-induced denaturation) and stabilization (e.g., water replacement, vitrification, preferential hydration, and molecular confinement) all contribute to the stability of proteins in DMN matrices. Other processes also modulate these processes, such as polymer–protein interactions, residual moisture, glass-transition behavior, molecular mobility and microenvironmental physicochemical conditions. The rational engineering of polymer matrices, excipients systems and processing conditions therefore is the key to preserving a higher-order protein structure while providing sufficient mechanical properties, quick dissolution, higher drug loading efficiency and reproducible intradermal delivery. In recent years, a wide range of multifunctional biomaterials, hybrid polymer architectures, carrier-free insulin formulations and stimuli-responsive matrices have significantly broadened the design space for insulin and other biologic formulations that enables their stabilization during ambient and accelerated storage. Moreover, recent developments in biophysical characterization, solid-state analytical methods and computational modeling have helped to gain insight into formulation–structure–function relationships, and accelerated the rational optimization of protein-loaded DMN systems. Yet, there are still many difficulties to overcome for long-term stability, scalable manufacturing, quality-by-design implementation, regulatory standardization and global deployment. By combining mechanistic protein biophysics, pharmaceutical formulation and translational manufacturing, a platform for robust, cold-chain independent dissolving microneedles with a wide range of clinical applications across next-generation biologic therapeutics can be built.

9 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SYSangeeta Yanglem
Sangeeta Yanglem
BLBorish Loushambam
Borish Loushambam
SSSorokhaibam Mexico Singh
Sorokhaibam Mexico Singh
SVSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Neurotoxicity is generally thought to result from exogenous agents like environmental chemicals, drugs and biological toxins. However, increasing evidence suggests that many endogenous molecules that play a critical role in normal brain function can become neu-rotoxic when the regulatory mechanism involved in their production, metabolism, com-partmentalization and clearance are disrupted. This shift underlies the basis of endoge-nous neurotoxicity. This review discusses the major endogenous sources of neurotoxicity: metabolic neuro-toxins, dysfunctional neurotransmitters, protein aggregates and inflammatory mediators. These endogenous factors arise from different physiological pathways, but share common pathogenic mechanisms, all of which involve an underlying state of oxidative stress, mi-tochondrial dysfunction, impaired proteostasis, excitotoxic signalling, neurovascular dysfunction and maladaptive neuroglial responses. This is not a singular process but a network of interconnected processes, which work together to progressively diminish neu-ronal resilience and promote synaptic dysfunction and neurodegeneration. The review also underscores the critical role of astrocytes, microglia and other glial cells in the maintenance of neuronal homeostasis. By integrating diverse endogenous neurotoxic pathways within a unified homeosta-sis-centred framework, this review provides a broader perspective on the mechanisms linking metabolic disorders, aging and neurodegenerative diseases. This framework sug-gests that effective therapeutic strategies may require restoration of physiological regula-tory networks rather than targeting individual neurotoxic molecules in isolation. A sys-tems-level understanding of endogenous neurotoxicity may therefore facilitate the devel-opment of earlier biomarkers and more effective interventions aimed at preserving neu-ronal homeostasis and preventing progressive neurological dysfunction.